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A B ST R A C T
The aim o f this study was to investigate whether conventional polychem otherapy o f acute lymphoblastic leu­
kemia patients contributed to the developm ent o f oxidative stress and antioxidants depletion. Plasma levels of 
thiobarbituric acid-reactive substances assessed by malonedialdehyde (M DA) content were measured as 
products o f lipid peroxidation. Pretreatm ent MDA values and M DA values during therapy course were esti­
mated to be above the normal range, indicating the occurrence o f oxidative stress. Serum iron levels were 
monitored as a potential source o f  non-transferrin bound iron with a role in initiation o f  oxidative burst. In­
creased serum iron levels were measured during the whole course o f  chemotherapy. To analyze the effects o f  
cytostatic therapy on the pro-oxidant/antioxidant parameters in plasma we measured the total antioxidant 
status (TAS) and a single plasma antioxidant - uric acid (UA). A significant reduction o f TAS levels was found 
at the end o f the therapy course, strongly correlating with UA content (r=0,9; p<0,05). Our data suggest that 
uric acid as a routine laboratory indicator could also serve as a marker o f  blood antioxidant capacity.
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IN T R O D U C T IO N
Cancer is associated with increased formation o f  reactive 
oxygen species (ROS) and depletion o f  plasma and cellular 
antioxidants (1,3,7). The degree o f  lipid peroxidation in pa­
tients o f  acute lymphoblastic leukemia (ALL) was studied 
as a marker o f  disease activity (8). Chemotherapy and radi­
ation therapy are also associated with increased plasma 
lipid hydroperoxides and thiobarbituric acid-reactive sub­
stances (TBARS) (4,9,12,13,15). W hat is more, there is ev­
idence that a variety o f  anticancer drugs exert their 
cytotoxic activity by a free-radical-mediated mechanism 
(5,10). These drugs include anthracyclines, such as 
fannorubicin and cyclophosphamide (4,6,13). Treatment o f  
acute leukemias with high doses o f  cytotoxic drugs could 
overwhelm the cell antioxidative resistance mechanisms 
and lead to a condition known as oxidative stress (5). It still 
remains unclear whether ALL patients who underwent 
conventional polychemotherapy would show signs o f  oxi­
dative stress and antioxidant depletion in the course o f  their 
treatment. The assessment o f  their serum antioxidant status
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and levels o f  lipid peroxidation could be crucial for the evo­
lution o f  future therapeutic strategies.
M A T E R IA L  A N D  M E T H O D S
The study was perfonned between October 2001 and 
March 2003 at the Clinics o f  Hematology o f  St. Marina 
University Hospital o f  Varna and the Department o f  Pre­
clinical, Clinical Pharmacology and Biochemistry o f  Prof. 
Paraskev Stoyanov Medical University o f  V arna Oxidative 
stress and antioxidant capacity were investigated in a se­
lected group o f  8 patients (3 males, mean age 31,7 years, 
and 5 females, mean age 32,4 years), hospitalized for treat­
ment o f  ALL, who gave their informed consent to partici­
pation in the study. The morphological variant o f  leukemia 
was defined according to the FAB classification and pa­
tients' W HO performance status was estimated prior to the 
treatment (Table 1). Eligible for the study were only novel 
untreated lymphoblastic leukemia patients. Patients with 
high number o f  blast cells (over 30 ,109/I) were excluded 
from the study due to expected chemotherapy-induced 
hyperuricemia as a  result o f  tumor-lysis syndrome. All pa­
tients were treated with cytostatics according the protocols 
HCVAD applied in the Clinics o f  Hematology (Table 2). 
None o f  them had laboratory or clinical evidence o f  renal 
failure. Patients with clinical or biochemical features o f
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acute infection or inflammation were пот enrolled in the 
study.
Table I. Laboratory indices and  morphological variant 
o f  leukemia
♦Data are presented as median
Table 2. Cytostatic protocol HCVAD for treatment o f  
ALL patents
Cyclophosphamide 2 x 300mg/m2 iv 1 -3 days
Vinblastin 10mg iv 4th, 11th days
Farmorubicin 50mg/m2 iv 4th day
Dexamethazone 40mg iv
1 -4  and 
11-14 days
Severe liver disease was excluded by means o f  clinical, bio­
chemical and ultrasound examinations. No patient was af­
fected by wasting syndrome (body mass index was be­
tween 20,9 and 28,0).
The applied restrictions reduced the number o f  the patients 
included in the study to 8. Routine laboratory tests were car­
ried out before the treatment: differential blood count, blood 
hemoglobin, serum glucose, creatinine, and total protein 
levels, serum AsAT, ALAT, GGT, alkaline phosphatase, 
and LDH activities.
A group o f  14 healthy volunteers (mean age 41,4 ±12,7 
years: 6 males and 8 females) was used as a  control. Exclu­
sion criteria for control subjects were presence o f  neurolog­
ical or endocrinological diseases, diabetus mellitus, arterial 
hypertension, prior myocardial infarction or stroke, infec­
tions, other inflammatory or malignant diseases.
Neither patients, nor controls were given vitamin-mineral 
supplements.
Blood sample collection
Blood samples from patients were collected one day before 
administration o f  cytotoxic drugs and on the Iя, 4th, 7dl day 
o f  chemotherapy, and on the day when leukocyte count was 
lower than 1 x 109/1 (nadir) under standardized conditions. 
To obtain serum the blood was incubated for 20min at 37°C 
and after that centrifuged at 3000xg for 1 Omin. Plasma was
obtained by centrifugation o f blood (2000xg for 20min). 
Serum and plasma were immediately transferred into coded 
plastic tubes, snap frozen and stored at -22°C until analysis. 
The assays were carried out after thawing the frozen 
aliquots for 5min in a water-bath at 37°C and mixing them 
gently.
Differential blood count, total antioxidant status, and uric 
acid, malondialdehyde, serum iron, and total and direct bili­
rubin content were detemiined for all patients before and in 
the course o f  the chemotherapy cycle.
Serum antioxidant status and lipid peroxidation assay 
Serum oxidative stress was measured as described by Por­
ter at al. ( 17) by the content o f  TB ARS used as a  marker for 
lipid peroxidation in serum. Malondialdehyde (MDA), an 
end product o f  lipid peroxidation, was determined spectro- 
photometrically at 532nm on Specol 11 and was presented 
as nmol/ml serum. 1,1,3,3-tetramethoxypropan from 
Aldrich-Chemie (Steinheim, Germany) was used as a stan­
dard.
Serum iron levels were monitored as a potential source o f 
NTB1 with a  role in initiation o f  oxidative burst. Serum iron 
content was determined by the standard colorimetric test 
with ferrozine (SPINREACT, S. A.). The measurements 
were performed on automated multichannal analyzer 
COBAS MIRA.
Total antioxidant status was estimated using the Total anti­
oxidant status kit (RANDOX Laboratories Ltd., Ardmore, 
UK) based on the method o f  Miller et al. (14). This method 
measures the overall capacity o f  human serum antioxidants 
to quench ABTS radical cation (ABTS+), expressed as 
mmol TROLOX equivalents per liter. The measurements 
were performed using an automated multichannal analyzer 
ABBOTT SPECTRUM  EPX.
The levels o f  uric acid (UA) in serum were detemiined as 
compounds o f  the antioxidant defense (2). UA content was 
evaluated using enzymatic colorimetric test (URICASE- 
PAP) based on Trinder-Reaction. The measurements were 
performed on automated multichannal analyzer COBAS 
MIRA.
Statistical analysis
Paired t test was used to compare the baseline values (0 
day) with the values on days 1,4, 7, and on nadir, p -val. o f  
<0,05 were regarded as significant. The independent t test 
was used to compare groups o f  patients. Correlation was 
quantified using Spearman rank correlation coefficient test. 
All statistical analysis was performed using SPSS 11.1.0 
statistical software.
R E SU L T S A N D  D ISC U SSIO N
TAS levels o f  healthy volunteers were measured to be in 
the reference range o f  the method: l,30-l,77m m ol/l serum 
(mean value for the control group - 1,49 ±0,11 тто 1 Л  se­
rum). Before chemotherapy serum TAS values o f  patients 
were below the lower range values o f  the controls - 1,27
Laboratory indices ALL in acute phase of disease
Hemoglobin [g/l]* 80.5
White blood cells x 109/1* 11.2
Platelets x 104/l* 26.0
3 otal bilirubin [ mol/1]* 14.0
WHO
WHO, - 1, W HO,-2, 
W H03 -4 , WHO4 - I
1 FAB classification L2- 8
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±0,17 mmol/l (Table 3) followed by an increase o f  serum 
TAS values at the Iя and 4dl days o f  chemotherapy: 11% in­
crease at the 1st day and 9%  at day 4 during chemotherapy. 
Slightly lower TAS values were measured at the 7th day o f 
chemotherapy. On the nadir the decrease was o f  15% and 
was statistically significant (p<0,05 vs. day 0).
UA values were 219 ±85 mol/1 serum prior treatment and 
were within the nonnal range (mean value o f  the control 
group - 242 ±10 mol/1 serum for women; 299 ±25 mol/1 for 
men; reference range o f  the method: women - 148-357 
mol/1; men - 200-416 mol/1) (Table 3).
Serum levels o f  bilirubin considered as a potential antioxi­
dant in blood ( 11) did not show variations before and dur­
ing chemotherapy o f  all ALL patients (data not shown). 
The concentration o f  plasma M DA was estimated to be 
within the range o f  2,31 to 5,70nmol/ml for the control 
group (mean value - 3,98 ±l,19nm ol/m l). Pretreatment 
M DA levels were determined to be 7,72 ±2,72nmol/ml and 
significantly higher (p<0,05 vs. controls). A  slight decrease 
in M DA values was measured in the whole course o f  che­
motherapy, however, not statistically significant (p>0,05). 
On the nadir this parameter was determined to be lowest
Table 3. Changes in b lood antioxidanl/procxidant param eters in the course o f  conventional chem otherapy o f  ALL 
















1.27 +0.17 1.41 ±0.22 1.38 ±0.16 1.20 ±0.20 1.07 ±0.10* 1.49 ±0.11
UA
[mol/l]





7.72 ±2.72 6.71 ±1.61 7.01 ±3.81 7.53 ±5.09 6.30 ±2.54 3.98 ±1.19
Fe 
[ mol/'l]
26.0 ±12.6 33.4 ±11.4* 36.8 ±13.2 35.6 ±14.1 32.8 ±11.0
Î 13.8 ± 3.1 
+ 19.8 ±4.3
* - p<0,05 vs. day 0; J - women; t  - men
UA concentration increased soon after administration o f  
cytostatics (by 14% on the 1st day vs. day 0) and kept in­
creasing up to the 4th day (by 35%  on the 4th day vs. day 0).
Days
Fig. 1. Comparison between the changes in TAS and UA 
average values in ALL patients during chemotherapy 
course (Spearman rank correlation coefficient was 0,9 
(p<0,05)
A reduction o f  serum UA concentrations in the course o f  
chemotherapy was later measured, and was statistically sig­
nificant (p <0,05) on the nadir (24% decrease). Data analy­
sis revealed a strong correlation between UA as an antioxi­
dant and serum TAS measured: r=0,9; p<0,05 (Fig. 1).
(6,3nmol/ml) as compared to the M DA pretreatment values 
but it was still exceeding the control values. Evidence o f  in­
creased lipid peroxidation in serum as measured by M DA 
content did not correlate with decreased antioxidant capac­
ity, estimated as TAS values (r=0,1; p<0,05).
Total serum iron significantly increased on the first day o f  
the administration o f  cytostatics (p<0,05 vs. day 0) and kept 
increasing, exceeding the norm (reference values for 
women: 6,6-26,0 mol/1, mean value 13,8 ±3,1 mol/l; for 
men: 10,7-28,6 mol/l, mean value 19,8 ±4,3 mol/l) during 
the whole course o f  treatment. High serum iron still did not 
negatively correlate with TAS values (r=0,3) and with UA 
values (f =0,05; p=0,4).
The pathophysiology o f  cancer is associated with the in­
creased generation o f  reactive oxygen species and lipid 
peroxidation processes (1,3,7). M DA in untreated newly 
diagnosed patients with acute ALL was estimated to be 
above the nonnal range, indicating the occurrence o f  oxida­
tive stress. Our findings are in agreement with previously 
reported data demonstrating lipid peroxidation in acute 
leukemias (8) and free radical generation in patients with 
other types o f  cancer (13). M DA levels in treated patients 
did not remarkably change and were exceeding the control 
values over the time period studied, being thus a  marker for 
prevalence o f  processes o f  lipid peroxidation above antioxi­
dant defense. An increase in lipid peroxidation after high
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dose chemotherapy has oeen previously reported (4), indi­
cating a  free radical generation occurrence. An initiator o f 
free radical generation through Fenton reaction is NTBI. 
Elevated total serum iron could be a potential source o f 
NTBI. We measured increased serum iron levels during the 
whole course o f  conventional chemotherapy o f  ALL pa­
tients.
Blood total antioxidant status is the result o f  the interaction 
o f  many different compounds such as uric acid and antioxi­
dants o f  dietary origin and systemic metabolic interactions, 
and also by thiol groups o f  proteins. Despite the evidences 
for increased pretreatment lipid peroxidation, TAS and UA 
content measured were within the normal range before the 
chemotherapy. Chemotherapy-induced free radical genera­
tion and oxidative stress probably lead to the consumption 
o f  important antioxidants, including UA followed by a  de­
crease in serum TAS. However, an elevated content and not 
a  consumption o f  total serum antioxidants and UA were de­
tected already on days 1 and 4 o f  chemotherapy course. 
This could rather be a result o f  the release o f  intracellular 
antioxidants during the cytostatics-induced lysis o f  blast 
cells than a result o f  an up-regulation o f  antioxidants in­
duced by disease-related oxidative stress, as suggested ear­
lier (12,16). Monitoring o f  serum bilirubin, considered in 
recent times as a  potential antioxidant in blood (11), did not 
reveal changes in its levels during the course o f  treatment 
and thus could not contribute to the variations o f  TAS.
C O N C L U SIO N
Our data suggest that UA content as a  routine laboratory in­
dex could also serve as a  marker o f  blood antioxidant ca­
pacity. UA content monitoring in the course o f  chemother­
apy could indicate the moment when antioxidant 
supplementation therapy would compensate certain side ef­
fects o f  many anticancer drugs. Supplementation o f  antiox­
idants might affect clinical outcome and improve quality o f  
patients' life.
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